Why Shadow AI Is Your Biggest Security Risk in 2025

Insilico Medicine has reduced the time needed to produce some drug development candidates to about one year by combining artificial intelligence with laboratory research in China, according to CEO Alex Zhavoronkov.

The Hong Kong-listed company’s fastest programme reached candidate nomination in nine months, while its typical timeline is about 13 months, Zhavoronkov said. He said conventional approaches usually take about four-and-a-half years to reach the same stage.

The timeline covers early discovery and candidate selection, rather than the full process of bringing a drug to market. Clinical trials, manufacturing, and regulatory review remain separate stages

AI shortens candidate selection

The Hong Kong-listed company’s fastest programme reached candidate nomination in nine months, while its typical timeline is about 13 months, Zhavoronkov said. He said conventional approaches usually take about four-and-a-half years to reach the same stage.

The timeline covers early discovery and candidate selection, rather than the full process of bringing a drug to market. Clinical trials, manufacturing, and regulatory review remain separate stages

AI shortens candidate selection

The Hong Kong-listed company’s fastest programme reached candidate nomination in nine months, while its typical timeline is about 13 months, Zhavoronkov said. He said conventional approaches usually take about four-and-a-half years to reach the same stage.

The timeline covers early discovery and candidate selection, rather than the full process of bringing a drug to market. Clinical trials, manufacturing, and regulatory review remain separate stages